News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,897 Results
Type
Article (39145)
Company Profile (283)
Press Release (648469)
Section
Business (203900)
Career Advice (1996)
Deals (35371)
Drug Delivery (89)
Drug Development (80847)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344639)
Policy (32450)
Tag
Academia (2530)
Alliances (49183)
Alzheimer's disease (1257)
Approvals (16049)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64693)
Collaboration (482)
Compensation (260)
COVID-19 (2541)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6170)
Earnings (84892)
Employer resources (146)
Events (110006)
Executive appointments (394)
FDA (16767)
Funding (426)
Gene therapy (195)
GLP-1 (597)
Government (4333)
Healthcare (18693)
Infectious disease (2633)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16339)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19192)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1693)
Obesity (258)
Opinion (183)
Patents (117)
People (56455)
Phase I (20119)
Phase II (28493)
Phase III (21238)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21664)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1460)
Startups (3562)
United States (15141)
Vaccines (563)
Weight loss (181)
Date
Today (18)
Last 7 days (580)
Last 30 days (2363)
Last 365 days (35189)
2024 (35002)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54087)
2019 (46541)
2018 (35020)
2017 (32109)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37266)
Australia (6087)
California (3809)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79824)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1693)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1460)
Texas (547)
Utah (108)
Washington State (399)
687,897 Results for "scynexis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
December 19, 2024
·
4 min read
Press Releases
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
October 10, 2024
·
1 min read
Business
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.
May 8, 2024
·
9 min read
Press Releases
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 7, 2024
·
10 min read
Business
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2023.
March 28, 2024
·
11 min read
News
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
October 3, 2024
·
3 min read
Drug Development
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
SCYNEXIS, Inc. announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 at the ESCMID Global 2024 congress in Barcelona, Spain from April 27-30, 2024.
April 30, 2024
·
7 min read
Pharm Country
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET.
January 30, 2024
·
1 min read
Pharm Country
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024.
April 9, 2024
·
5 min read
Business
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
August 27, 2024
·
1 min read
1 of 68,790
Next
